Research progress on anti-cancer mechanism of salidroside regulating miRNA-mRNA signaling axis
Author:
Wu Xiaoxiong1, Zhang Zhendong1, Wang Xiaoping1
Affiliation:
1. School of Medicine , Xizang Minzu University , Xianyang , Shaanxi , China
Abstract
Abstract
MiRNA (MicroRNA) can target and regulate mRNA, thereby influencing the biological processes of tumors. The extract of Tibetan medicine Rhodiola demonstrates anti-tumor effects by targeting and regulating cancer-related signaling molecules and pathways. This review aims to pave the way for integrating salidroside into clinical practice, fully leverage its multi-effective and multi-targeted biological effects, and innovate approaches to tumor prevention and management, thus enhancing cancer prognosis. We initially delve into the occurrence and mechanism of action of miRNA, as well as the anti-tumor mechanism of the miRNA-mRNA signaling axis. Additionally, it was described that salidroside can hinder cancer cell proliferation by inducing autophagy and apoptosis, inhibiting cell metastasis and invasion, and modulating the tumor microenvironment and cell cycle. Moreover, examples from lung cancer, gastric cancer, and nasopharyngeal carcinoma confirm that salidroside regulates the onset and progression of tumors through the miRNA-mRNA signaling axis. This groundbreaking discovery carries significant implications for cancer diagnosis and treatment, offering a novel pathway for therapeutic intervention.
Funder
The Innovation and Entrepreneurship Training Program for College Students in 2024 The Key Scientific Research Program of Xizang Autonomous Region and Xizang Minzu University The Natural Science Basic Research Plan in Shaanxi Province of China Graduate Research Innovation and Practice Projects Research Project of Chunhui Plan of Ministry of Education of China The Central Guidance on Local Science and Technology Development Fund of Tibet Autonomous Region
Publisher
Walter de Gruyter GmbH
Reference77 articles.
1. Miller, KD, Siegel, RL, Lin, CC, Mariotto, AB, Kramer, JL, Rowland, JH, et al.. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 2016;66:271–89. https://doi.org/10.3322/caac.21349. 2. Miller, KD, Fidler-Benaoudia, M, Keegan, TH, Hipp, HS, Jemal, A, Siegel, RL. Cancer statistics for adolescents and young adults, 2020. CA Cancer J Clin 2020;70:443–59. https://doi.org/10.3322/caac.21637. 3. Miller, KD, Nogueira, L, Devasia, T, Mariotto, AB, Yabroff, KR, Jemal, A, et al.. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin 2022;72:409–36. https://doi.org/10.3322/caac.21731. 4. McCawley, N, Clancy, C, O’Neill, BD, Deasy, J, McNamara, DA, Burke, JP. Mucinous rectal adenocarcinoma is associated with a poor response to neoadjuvant chemoradiotherapy: a systematic review and meta-analysis. Dis Colon Rectum 2016;59:1200–8. https://doi.org/10.1097/dcr.0000000000000635. 5. Scatchard, K, Forrest, JL, Flubacher, M, Cornes, P, Williams, C. Chemotherapy for metastatic and recurrent cervical cancer. Cochrane Database Syst Rev 2012;10:CD006469. https://doi.org/10.1002/14651858.cd006469.pub2.
|
|